Lead-212
- Generic Name
- Lead-212
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
Phase 1
Not yet recruiting
- Conditions
- Head and Neck TumorsSomatostatin Receptor PositiveKidney CancersSmall Cell Lung CancersPheochromocytoma/ParagangliomasGastrointestinal Neuroendocrine Tumors
- Interventions
- First Posted Date
- 2024-06-28
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 120
- Registration Number
- NCT06479811
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
Phase 1
Recruiting
- Conditions
- Somatostatin Receptor PositiveGastrointestinal Neuroendocrine TumorsParagangliomasPheochromocytoma
- Interventions
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 66
- Registration Number
- NCT06427798
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath